Clinical Trials Browser

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Phase 2 Completed

247 enrolled 27 charts

Breast

Breast Neoplasms

NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Phase 2 Completed

40 enrolled 13 charts

Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

NCT04300790 2025-07-29

METALLICA

Phase 2 Completed

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2 Completed

162 enrolled 12 charts

Breast

Breast Neoplasms

NCT03219476 2025-04-29

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Phase 2 Completed

37 enrolled 10 charts

Breast

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

Phase 2 Completed

36 enrolled 17 charts

Breast

Breast Neoplasms

NCT02188745 2024-07-17

POLLY

Phase 2 Completed

19 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02676986 2024-07-05

ARB

Phase 2 Completed

221 enrolled

Breast

Primary Breast Cancer ER+ve

NCT01594216 2024-06-12

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Phase 2 Completed

25 enrolled 8 charts

Breast

Estrogen-receptor Positive Invasive Metastatic Breast Cancer

NCT04129216 2024-05-07

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

Phase 2 Completed

30 enrolled 10 charts

Breast

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

Phase 2 Completed

257 enrolled

Breast

Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Phase 2 Completed

30 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Completed

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT03312738 2024-01-23

BOLERO-5

Phase 2 Completed

159 enrolled 25 charts

Breast

Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast

Breast Neoplasms

NCT04465097 2023-10-17

NeoTEE

Phase 2 Completed

30 enrolled

Breast

Breast Neoplasms

NCT02028364 2023-08-24

PEARL

Phase 2 Completed

55 enrolled

Breast

Breast Neoplasms

NCT02598557 2023-08-22

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Phase 2 Completed

180 enrolled 46 charts

Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT03555877 2023-07-07

AMICA

Phase 2 Completed

56 enrolled

Breast

Breast Cancer Metastatic

NCT02666105 2023-05-31

Exemestane in Post-Menopausal Women With NSCLC

Phase 2 Completed

6 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01698918 2023-05-03

BOLERO-4

Phase 2 Completed

202 enrolled 19 charts

Breast

Breast Neoplasms

NCT02894398 2023-03-13

INGE-B

Phase 2 Completed

388 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00128843 2023-03-06

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Phase 2 Completed

103 enrolled

Breast

Breast Neoplasms

NCT02049957 2023-02-08

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Phase 2 Completed

118 enrolled 30 charts

Breast

Breast Neoplasms

NCT02440230 2022-12-30

SEAT

Phase 2 Completed

110 enrolled

Breast

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

Phase 2 Completed

160 enrolled

Breast

Breast Neoplasms

NCT03291886 2022-06-21

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Phase 2 Completed

133 enrolled

Breast

Breast Neoplasms

NCT01783444 2021-02-26

BOLERO-6

Phase 2 Completed

309 enrolled 19 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04659551 2020-12-09

GIADA

Phase 2 Completed

43 enrolled

Breast

Breast Neoplasms

NCT00810797 2020-10-19

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

Phase 2 Completed

36 enrolled 8 charts

Breast

Breast Neoplasms

NCT01963481 2020-03-17

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

Phase 2 Completed

23 enrolled 10 charts

Metastatic Beast Cancer

NCT02291913 2020-02-17

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Phase 2 Completed

48 enrolled 13 charts

Breast

Breast Neoplasms

NCT01381874 2019-04-11

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Phase 2 Completed

297 enrolled 19 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast

Breast Neoplasms

NCT00201864 2018-07-26

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

Phase 2 Completed

40 enrolled 12 charts

Breast

Breast Neoplasms

NCT00728949 2018-06-06

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Phase 2 Completed

93 enrolled 14 charts

Breast

Breast Neoplasms

NCT00941330 2017-04-10

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

Phase 2 Completed

31 enrolled 8 charts

Breast

Breast Neoplasms

NCT01654185 2017-03-14

Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer

Phase 2 Completed

60 enrolled

Breast

Breast Neoplasms

NCT02069093 2017-02-13

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Phase 2 Completed

92 enrolled 9 charts

Breast

Advanced Breast Cancer

NCT00073073 2016-05-17

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

Phase 2 Completed

46 enrolled 8 charts

Breast

Breast Neoplasms

NCT01151046 2016-05-12

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Phase 2 Completed

118 enrolled 13 charts

Breast

Breast Neoplasms

NCT00010010 2016-03-11

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Phase 2 Completed

Breast

Breast Neoplasms

NCT01004081 2015-10-02

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Phase 2 Completed

54 enrolled

Breast

Breast Neoplasms

NCT00201773 2015-06-30

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

Phase 2 Completed

22 enrolled 9 charts

Breast

Breast Neoplasms

NCT00767520 2013-02-28

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Phase 2 Completed

155 enrolled 19 charts

Breast

Breast Neoplasms

NCT00031889 2012-05-15

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

Phase 2 Completed

5 enrolled

Genitourinary

Prostatic Neoplasms

NCT00174343 2011-04-22

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Phase 2 Completed

46 enrolled

Breast

Breast Neoplasms

NCT00261027 2010-03-02

Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer

Phase 2 Completed

30 enrolled

Gynecologic

Ovarian Neoplasms

NCT00919399 2009-06-12

TAMARO

Phase 2 Completed

15 enrolled

Breast

Breast Neoplasms